Ecnoglutide: The cAMP-Biased GLP-1 Analog From China, By the Trial Data

AI generatedglp-1weight-lossemerging
This article was AI-generated for informational purposes only. It is not medical advice. Always verify claims with the cited sources.

Most of the GLP-1 receptor agonists that dominate headlines — semaglutide, tirzepatide — were developed in the United States or Europe. Ecnoglutide is a different story. Developed by Sciwind Biosciences, a metabolic-disease company headquartered in Hangzhou, China (CEO Dr. Hai Pan), ecnoglutide (development code XW003) is a once-weekly injectable GLP-1 analog engineered around an unusual design goal: signaling bias. This entry logs what the peer-reviewed Phase 3 data actually show, and — importantly — where its regulatory status stands.

Research log: what "cAMP-biased" means

GLP-1 receptors, once activated, can signal down more than one pathway. Two matter here: the cAMP pathway (which drives insulin secretion) and beta-arrestin recruitment (which is associated with receptor internalization — the receptor being pulled inside the cell, where it can no longer respond). Ecnoglutide is described in its Phase 3 publications as a cAMP signaling-biased GLP-1 analog, meaning it preferentially activates cAMP signaling over beta-arrestin recruitment.

The stated rationale, quoted directly from the EECOH-1 trial paper: "cAMP bias is hypothesised to enhance the clinical efficacy of GLP-1 receptor agonists through reducing internalisation of the GLP-1 receptor and enhancing insulin secretion." In plain terms, the design bet is that keeping receptors active at the cell surface longer could sustain the drug's effect. That is a mechanistic hypothesis — the clinical value ultimately rests on the trial outcomes below, not on the mechanism alone.

The obesity Phase 3 trial

The weight-management data were published in The Lancet Diabetes & Endocrinology in 2025 (registration NCT05813795). It was a multicentre, randomised, double-blind, placebo-controlled Phase 3 trial run across medical centres in China, enrolling 664 adults aged 18–75 with overweight or obesity but without diabetes. Three once-weekly subcutaneous doses (1.2 mg, 1.8 mg, 2.4 mg) were compared against placebo over 40 weeks.

At week 40, mean body-weight reductions were:

  • 1.2 mg: −9.1%
  • 1.8 mg: −10.9%
  • 2.4 mg: −13.2%
  • Placebo: +0.1%

    • Treatment differences versus placebo ranged from roughly −9.2% to −13.3% (p<0.0001). The proportion of participants losing at least 5% of body weight was 77%, 84%, and 87% across the three doses, versus 16% on placebo. As with the rest of the GLP-1 class, the most common adverse events were mild-to-moderate gastrointestinal effects; adverse events occurred in about 93% of treated participants versus 84% on placebo, and ten participants discontinued because of adverse effects.

    For context, these figures sit in the same neighborhood as — though from separate trials and not head-to-head against — the weight loss reported for semaglutide. Cross-trial comparisons are not apples-to-apples, so treat any ranking as informal.

    The type 2 diabetes Phase 3 program

    Ecnoglutide also carries a diabetes dataset, published across The Lancet Diabetes & Endocrinology and Nature Communications in 2025. Two pivotal trials anchor it:

  • EECOH-1 — a randomised, double-blind, placebo-controlled trial in adults with type 2 diabetes inadequately controlled by diet/exercise or a single oral agent. At week 24, HbA1c fell −1.96% (0.6 mg) and −2.43% (1.2 mg) versus −0.87% on placebo (treatment differences of −1.09% and −1.56%, respectively). Dosing was once-weekly subcutaneous injection via pen, with a dose-escalation schedule.
  • EECOH-2 — a 52-week, open-label, active-controlled non-inferiority trial comparing ecnoglutide (0.6 mg or 1.2 mg once weekly) against dulaglutide 1.5 mg once weekly in adults on metformin.

    • The diabetes doses (0.6 / 1.2 mg) are notably lower than the obesity doses (up to 2.4 mg), reflecting the two different indications.

    Regulatory status — read this part carefully

    Ecnoglutide is approved in China. China's National Medical Products Administration (NMPA) approved ecnoglutide injection for chronic weight management in adults with overweight or obesity (highest approved dose 2.4 mg), and Sciwind reports a separate Chinese approval for type 2 diabetes. Sciwind has described it as the world's first approved biased GLP-1 receptor agonist.

    Crucially: ecnoglutide is not approved by the U.S. FDA. Approval in China does not mean availability, approval, or legal marketing in the United States. Anyone tracking peptide regulatory status should treat a foreign approval and an FDA approval as entirely separate events. For how PepStash categorizes approval and legal standing, see the FDA status reference. Regulatory pipelines move, so verify the current status against primary regulatory sources before drawing conclusions.

    Bottom line

    Ecnoglutide is a genuinely novel entry: a Chinese-developed, once-weekly, cAMP-biased GLP-1 analog with peer-reviewed Phase 3 data in both obesity (up to ~13% mean weight loss at 40 weeks) and type 2 diabetes, and a Chinese regulatory approval to match. It is also, at the time of writing, unapproved in the U.S. — a reminder that the GLP-1 field is now genuinely global, and that "approved" always means "approved where."

    PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.

    Not medical advice. For research purposes only. Consult a licensed physician before beginning any protocol.